Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 293.00
Bid: 290.00
Ask: 293.00
Change: -3.00 (-1.01%)
Spread: 3.00 (1.034%)
Open: 286.00
High: 293.00
Low: 284.00
Prev. Close: 296.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Retailer ASOS now to be seen on London Main Market

Thu, 13th Jan 2022 09:10

(Alliance News) - Online fashion retailer ASOS on Thursday revealed plans to move to the London Main Market, saying it has outgrown AIM after 20 years, most of that time as its biggest listing.

ASOS, which stands for "as seen on screen", long dominated the junior market, though its current market capitalisation of GBP2.42 billion places it fifth in size on AIM. Currently the largest stock traded on AIM is Hutchmed (China) Ltd with a GBP4.18 billion market cap, followed by Abcam PLC and Fevertree Drinks PLC. The move would also put ASOS in contention to join the FTSE 250 index.

ASOS shares were up 8.2% at 2,443.00 pence in London on Thursday morning.

"ASOS directors believe that given ASOS's size and scale, now is the appropriate time to move from AIM to a premium Main Market listing," the company said, explaining it thinks the move will raise its corporate profile and recognition, and increase investment in its shares by global institutions.

ASOS said it will move its listing by the end of February. JP Morgan will act as sponsor for the Main Market admission, which won't involve any fund raise.

In conjunction with the shift, ASOS has hired Patrick Kennedy as senior independent director. Kennedy, the former chief executive of Irish betting firm Paddy Power - now Flutter Entertainment PLC - is the chair of Bank of Ireland Group PLC. He holds 23,000 ASOS shares, which are worth about GBP560,000.

ASOS also provided a trading update for the last four months of 2021.

Total revenue rose by 2.1% to GBP1.39 billion from GBP1.36 billion a year before. In constant currency, the increase was 5%. UK sales rose by 13%, while EU sales rose by 2% and US sales by 11%, both at constant currency. However, Rest of World sales fell by 15% at constant currency and by 20% at actual rates.

ASOS said that while UK sales benefited from Britons going out once again, the fourth wave of Covid-19 limited this in Europe. In the US, ASOS note significant port congestion and supply chain disruption, restricting its ability to fulfil orders. ROW sales also were hurt by "the continued impact of extended delivery propositions".

Gross margin narrowed by 400 basis points to 43.0%, as expected, ASOS said, due to clearance activity. The product returns rate has normalised in line with expectations.

ASOS said that, despite uncertainty related to the Omicron variant of Covid-19, its full-year guidance remains unchanged at 10% to 15% revenue growth and adjusted pretax profit of GBP110 million to GBP140 million. In the financial year that ended August 31, 2021, ASOS recorded GBP3.91 billion in revenue, up from GBP3.26 billion the year before, with adjusted pretax profit of GBP193.6 million, up from GBP142.1 million.

"Our listing on AIM for the past 20 years has been an important part of ASOS's development, but the time is now right to move to the Main Market as we focus on delivering our medium-term guidance and longer-term growth ambitions," said Chief Operating Officer Mat Dunn.

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
11 Nov 2019 11:08

Hutchison's Surufatinib Gets New Drug Application Approval In China

Hutchison's Surufatinib Gets New Drug Application Approval In China

Read more
10 Oct 2019 15:45

Hutchison China Meditech expands collaboration with Innovent

(Sharecast News) - Hutchison China Meditech on Thursday confirmed the expansion of its tumour treatment collaboration agreement with Innovent Biologics Inc..

Read more
10 Oct 2019 12:43

Hutchison China Expands Tumour Treatment Collaboration With Innovent

Hutchison China Expands Tumour Treatment Collaboration With Innovent

Read more
4 Oct 2019 15:21

Hutchison Chi-Med initiates latest study of HMPL-523

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated an international phase 1 and 1b study of 'HMPL-523' - its novel spleen tyrosine kinase inhibitor - in patients with relapsed or refractory lymphoma, it announced on Friday.

Read more
4 Oct 2019 10:26

WINNERS & LOSERS SUMMARY: Astra Rises On Fasenra Approval In US

WINNERS & LOSERS SUMMARY: Astra Rises On Fasenra Approval In US

Read more
4 Oct 2019 08:39

Hutchison China Doses First Patient In HMPL-523 Lymphoma Study

Hutchison China Doses First Patient In HMPL-523 Lymphoma Study

Read more
3 Sep 2019 13:25

Hutchison China Starts Trial For HMPL-689 On Lymphoma Treatment

(Alliance News) - Hutchison China MediTech Ltd said Tuesday it has started its phase 1/1b study of small molecule inhibitor HMPL-689 in patients with advanced relapsed or refractory in the firm at

Read more
23 Aug 2019 11:25

Hutchison China MediTech launches trial for autoimmune disorder treatment

(Sharecast News) - Hutchison China MediTech has launched a clinical trial of HMPL-523, a novel spleen tyrosine kinase inhibitor, in patients with immune thrombocytopenia, an autoimmune disorder that can lead to increased risk of bleeding.

Read more
23 Aug 2019 10:59

Hutchison China Meditech Starts HMPL-523 Trial In China

(Alliance News) - Hutchison China Meditech Ltd on Friday said it has begun a phase 1 study of HMPL-523 as a treatment for immune thrombocytopenia in China, dosing the first patient on Monday last

Read more
30 Jul 2019 11:43

Hutchison China Interim Loss Widens On Expenses; Alters 2019 Guidance

(Alliance News) - Hutchison China MediTech Ltd on Tuesday said its loss widened in the first half of the year due to expenses, while it has reduced guidance on expenses and cash flow.Shares

Read more
23 Jul 2019 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 24 July Tullow OilHalf Year ResultsPaypointQ1 Year ResultsLaw

Read more
3 Jul 2019 13:42

Prudential Holds 5% Hutchison China Meditech Stake After Deal

(Alliance News) - Hutchison China Meditech Ltd on Wednesday said Prudential PLC held a 5.1% stake in the China-focused drug company.Following a deal on Friday last week, Prudential held in

Read more
28 Jun 2019 16:38

Hutchison China Meditech Confirms Discounted Nasdaq Offer Pricing

(Alliance News) - China-focused drug developer and distributor Hutchison China Meditech PLC said Friday the pricing of a secondary offer of its Nasdaq-listed shares has been fixed at USD24.00 also

Read more
14 Jun 2019 14:40

Hutchison Chi-Med makes progress with surufatinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee (IDMC) of the phase 3 pivotal study of 'surufatinib' in advanced neuroendocrine tumors - extra-pancreatic (SANET-ep) had completed a planned interim analysis.

Read more
29 May 2019 12:38

Hutchison China Meditech Shareholders Approve Subdivision Of Shares (ALLISS)

LONDON (Alliance News) - Hutchison China Meditech Ltd on Wednesday said its shareholders have approved a subdivision of shares at its extraordinary general meeting.The pharmaceutical that a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.